Benefits of interferon-β and temozolomide combination therapy for newly diagnosed primary glioblastoma with the unmethylated MGMT promoter: A multicenter study.

@article{Motomura2011BenefitsOI,
  title={Benefits of interferon-β and temozolomide combination therapy for newly diagnosed primary glioblastoma with the unmethylated MGMT promoter: A multicenter study.},
  author={Kazuya Motomura and Atsushi Natsume and Yugo Kishida and Hiroyuki Higashi and Yutaka Kondo and Yoko Nakasu and Tatsuya Abe and Hiroki Namba and Kenji Wakai and Toshihiko Wakabayashi},
  journal={Cancer},
  year={2011},
  volume={117 8},
  pages={1721-30}
}
BACKGROUND The aim of the current study was to catalog genomic and epigenomic abnormalities in newly diagnosed glioblastoma patients and determine the correlation among clinical, genetic, and epigenetic profiles and clinical outcome. METHODS This study retrospectively included 68 consecutive patients who underwent surgical treatment and received standard radiotherapy with temozolomide (TMZ)-based chemotherapy. Of a total of 68 patients, 39 patients (57.4%) received interferon (IFN)-β in… CONTINUE READING